Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Enters Collaboration Agreement with Phasex Corporation

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the worldwide life sciences industry, this morning announced a collaboration with Phasex Corporation, one of the world’s most experienced supercritical fluid (“SCF”)-based toll processors. The goal of the collaboration is to combine PBI’s recently patented Ultra Shear Technology with Phasex’s SCF-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. “Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies,” Richard T. Schumacher, president and CEO of PBI, stated in the news release. “Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration.”

To view the full press release, visit http://dtn.fm/7IiPk

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing technologies.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO. Bookmark the permalink.

Comments are closed.